Neximmune Stock Cash And Equivalents
| NEXIDelisted Stock | USD 2.43 0.22 9.95% |
Neximmune fundamentals help investors to digest information that contributes to Neximmune's financial success or failures. It also enables traders to predict the movement of Neximmune Pink Sheet. The fundamental analysis module provides a way to measure Neximmune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neximmune pink sheet.
Neximmune |
Neximmune Company Cash And Equivalents Analysis
Neximmune's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Neximmune Cash And Equivalents | 53.13 M |
Most of Neximmune's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neximmune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Neximmune has 53.13 M in Cash And Equivalents. This is 93.53% lower than that of the Biotechnology sector and 88.12% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 98.03% higher than that of the company.
Neximmune Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neximmune's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Neximmune could also be used in its relative valuation, which is a method of valuing Neximmune by comparing valuation metrics of similar companies.Neximmune is currently under evaluation in cash and equivalents category among its peers.
Neximmune Fundamentals
| Return On Equity | -1.96 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | (491.95 K) | ||||
| Shares Outstanding | 1.37 M | ||||
| Shares Owned By Insiders | 17.00 % | ||||
| Shares Owned By Institutions | 11.17 % | ||||
| Number Of Shares Shorted | 15.99 K | ||||
| Price To Book | 1.38 X | ||||
| EBITDA | (28.17 M) | ||||
| Net Income | (32.34 M) | ||||
| Cash And Equivalents | 53.13 M | ||||
| Cash Per Share | 2.20 X | ||||
| Total Debt | 68.81 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 6.54 X | ||||
| Book Value Per Share | 2.00 X | ||||
| Cash Flow From Operations | (31.43 M) | ||||
| Short Ratio | 2.26 X | ||||
| Earnings Per Share | (24.11) X | ||||
| Target Price | 2.0 | ||||
| Beta | 1.94 | ||||
| Market Capitalization | 3.25 M | ||||
| Total Asset | 8.59 M | ||||
| Retained Earnings | (222.59 M) | ||||
| Working Capital | 316.73 K | ||||
| Net Asset | 8.59 M |
About Neximmune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neximmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neximmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neximmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Neximmune Pink Sheet
If you are still planning to invest in Neximmune check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neximmune's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |